Efficacy and Safety of Upadacitinib in a Phase II Randomised, Double-Blind, Dose-Ranging Study of Adults with Extensive Non-segmental Vitiligo

Vitiligo is an autoimmune skin disorder characterised by acquired distinct white patches of the skin. Currently, limited treatment options are available for vitiligo, and there are no approved systemic therapies. At the European Academy of Dermatology and Venereology (EADV) Congress in Berlin, Germany, 11th–14th October 2023, Thierry Passeron, Professor and Chair of Dermatology at the Côte d’Azur University, Nice, France, and Head of the Laboratory INSERM U1065 Team 12, Centre Méditerranéen de Médecine Moléculaire (C3M), Côte d’Azur University, Nice, France, presented an oral presentation summarising data from a Phase IIb study of upadacitinib, an oral selective JAK inhibitor, in patients with non-segmental vitiligo (NSV), during the ‘Free Communications II’ session. Passeron gave an overview of the multicentre, randomised, double-blind, placebo-controlled, dose-ranging study that evaluated the efficacy and safety of upadacitinib in adults with NSV. This article focuses on the clinical efficacy endpoints and the safety profile outcomes presented at the EADV congress. Overall, the study demonstrated the clinical efficacy of upadacitinib at 24 weeks at different doses versus placebo, with improvements in repigmentation over time, up to Week 52, with a favourable safety profile.